Azd-1222/elasomeran/tozinameranLymphadenopathy: 7 case reports

被引：0

|

作者：

机构：

来源：

Reactions Weekly | 2022年 / 1907卷 / 1期

关键词：

D O I：

10.1007/s40278-022-15361-z

中图分类号：

学科分类号：

摘要：

引用

收藏

页码：102 / 102

相关论文

共 50 条

[31] AZD-1222/Elasomeran/TozinameranVulval ulcers
Reactions Weekly, 2024, 1995 (1) : 38 - 38
[32] AZD-1222/elasomeran/tozinameranVarious toxicities
Reactions Weekly, 2024, 1992 (1) : 44 - 44
[33] Azd-1222/elasomeran/tozinameranAnti-LGI1 encephalitis: 4 case reports
Reactions Weekly, 2023, 1960 (1) : 89 - 89
[34] AZD-1222/Elasomeran/TozinameranBell's palsy
Reactions Weekly, 2023, 1987 (1) : 52 - 52
[35] AZD-1222/elasomeran/ibuprofenLofgren's syndrome and lack of efficacy: 2 case reports
Reactions Weekly, 2022, 1930 (1) : 121 - 121
[36] AZD-1222/elasomeran/tozinameranMultiple sclerosis (MS) and relapse of MS: 16 case reports
Reactions Weekly, 2022, 1896 (1) : 76 - 76
[37] Azd-1222/elasomeran/tozinameranKidney disorders, systemic lupus erythematosus and vasculitis: 17 case reports
Reactions Weekly, 2023, 1971 (1) : 55 - 55
[38] AZD-1222/elasomeran/tozinameranChronic spontaneous urticaria (CSU) and exacerbation of CSU: 8 case reports
Reactions Weekly, 2022, 1927 (1) : 122 - 122
[39] AZD-1222/elasomeran/ibuprofenSubacute thyroiditis, gastrointestinal intolerance and lack of efficacy: 2 case reports
Reactions Weekly, 2022, 1906 (1) : 101 - 101
[40] AZD-1222/elasomeran/tozinameranRetinal vein occlusion
Reactions Weekly, 2024, 2012 (1) : 66 - 66

← 1 2 3 4 5 →